Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M205,481Revenue $M49,605Net Margin (%)18.7Altman Z-Score2.8
Enterprise Value $M214,009EPS $1.4Operating Margin %25.9Piotroski F-Score6
P/E(ttm)23.2Beneish M-Score-2.7Pre-tax Margin (%)25.4Higher ROA y-yN
Price/Book3.110-y EBITDA Growth Rate %3.0Quick Ratio2.2Cash flow > EarningsY
Price/Sales4.35-y EBITDA Growth Rate %5.0Current Ratio2.5Lower Leverage y-yN
Price/Free Cash Flow16.4y-y EBITDA Growth Rate %-14.2ROA % (ttm)5.4Higher Current Ratio y-yY
Dividend Yield %3.2PEG4.6ROE % (ttm)12.4Less Shares Outstanding y-yY
Payout Ratio %73.0Shares Outstanding M6,158ROIC % (ttm)12.1Gross Margin Increase y-yN

Gurus Latest Trades with PFE

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFEKahn Brothers 2015-03-31 Reduce-0.39%$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 3.83%1,811,016
PFEJames Barrow 2015-03-31 Reduce-0.32%$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 12.24%55,080,222
PFENWQ Managers 2015-03-31 Reduce-0.16%$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 6.64%5,927,532
PFEJoel Greenblatt 2015-03-31 Add0.15%$31.16 - $35.05
($33.51)
$ 33.37-0%Add 38.84%1,972,788
PFECharles Brandes 2015-03-31 Reduce-0.07%$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 2.37%6,123,536
PFEDavid Dreman 2015-03-31 Add0.03%$31.16 - $35.05
($33.51)
$ 33.37-0%Add 70.38%25,202
PFEMario Gabelli 2015-03-31 Reduce-0.01%$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 5.80%896,431
PFEDodge & Cox 2015-03-31 Reduce-0.01%$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 0.89%46,776,959
PFERichard Pzena 2015-03-31 Reduce$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 0.50%2,159,618
PFEFirst Eagle Investment 2015-03-31 Reduce$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 0.12%5,266,820
PFEJohn Keeley 2015-03-31 Reduce$31.16 - $35.05
($33.51)
$ 33.37-0%Reduce 1.27%98,689
PFEKen Fisher 2015-03-31 Add$31.16 - $35.05
($33.51)
$ 33.37-0%Add 0.04%31,208,271
PFEKahn Brothers 2014-12-31 Reduce-0.49%$27.7 - $32.09
($30.23)
$ 33.3710%Reduce 5.14%1,883,217
PFEFirst Eagle Investment 2014-12-31 Add0.39%$27.7 - $32.09
($30.23)
$ 33.3710%Add 3786.85%5,272,943
PFERichard Pzena 2014-12-31 Buy 0.36%$27.7 - $32.09
($30.23)
$ 33.3710%New holding2,170,568
PFEVanguard Health Care Fund 2014-12-31 Add0.32%$27.7 - $32.09
($30.23)
$ 33.3710%Add 29.88%19,395,622
PFEMichael Price 2014-12-31 Sold Out -0.17%$27.7 - $32.09
($30.26)
$ 33.3710%Sold Out0
PFEKahn Brothers 2014-09-30 Reduce-0.59%$28.04 - $30.96
($29.58)
$ 33.3713%Reduce 6.56%1,985,161
PFEMichael Price 2014-09-30 Reduce-0.22%$28.04 - $30.96
($29.58)
$ 33.3713%Reduce 56.02%47,100
PFEFirst Eagle Investment 2014-09-30 Reduce-0.16%$28.04 - $30.96
($29.58)
$ 33.3713%Reduce 94.11%135,661
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these investors:


News about PFE:

Articles On GuruFocus.com
Despite Recent Downgrade, This Ecommerce Giant is a Buy Jun 29 2015 
Paul Tudor Jones' Top Three Stocks Deliver Positive Returns Jun 24 2015 
Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
A Look at James Barrow's Investment in Pfizer Jun 16 2015 
Jim Simons' Top 3 Positions and One That Doubled Return Jun 10 2015 
Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
Apple, SunEdison and Biogen: Hellman, Jordan Management's Top 3 Stocks Outperform the Rise in the S& May 28 2015 
Ken Fisher Adds to His Pfizer Position May 27 2015 
Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 
Amgen’s Cholesterol Fighting Drug Receives EU Approval May 26 2015 

More From Other Websites
6:13 am Pfizer and GlaxoSmithKline (GSK) JV ViiV Healthcare enters... Jul 02 2015
ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of... Jul 02 2015
[video]U.S. Companies Look to the U.K. for Investment Opportunites Jul 01 2015
U.S. doctors, hospitals reap $6.5 bln from drug and device makers -report Jun 30 2015
Big pharma to be grilled on tax avoidance Jun 30 2015
Why Jazz Pharmaceuticals Is Winning Jun 29 2015
Bank controls add to headaches for Greece's pharmacists Jun 29 2015
Dow falls 225 points, in the red for the year amid Greece; VIX spikes 24% Jun 29 2015
Is Big Pharma Advertising Getting Out of Control? Jun 26 2015
Valeant Pharmaceuticals And Zoetis: A True Mega Deal Is On The Horizon Jun 26 2015
Glaxo, Pfizer Meningitis B Vaccines Get ACIP's Category B - Analyst Blog Jun 25 2015
Zoetis Shares Surge After Report of Takeover Approach by Valeant Jun 25 2015
Pfizer Declares 28-Cent Third-Quarter 2015 Dividend Jun 25 2015
Joseph J. Echevarria Elected To Pfizer’s Board Of Directors Jun 25 2015
Joseph J. Echevarria Elected To Pfizer’s Board Of Directors Jun 25 2015
Pfizer Declares 28-Cent Third-Quarter 2015 Dividend Jun 25 2015
Lilly Blooms; Shares Up 4.5% on Patent Win, Merrill Upgrade Jun 25 2015
Short Sellers Become More Focused on Big Pharma Jun 25 2015
America's top states for innovation in 2015 Jun 24 2015
U.S. CDC updates recommendation for new meningitis B vaccines Jun 24 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

SEENSCO
ReplySEENSCO - 1 year ago
PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK